John has been with Putnam Associates since 1992, and has over 21 years of strategy consulting experience. John has counseled senior executives at numerous leading pharmaceutical and biotechnology companies, providing strategic support and recommendations on a wide array of issues, including pricing, contracting and reimbursement strategies, corporate strategy, new product commercialization, clinical trial development, and sales force optimization strategies. John has extensive experience in specialty pharmaceutical markets that comprise Oncology, Neurology, Immunology, Cardiovascular Disease, and Anti-Infectives. He is published in peer-review literature as a co-author on a study examining the cost effectiveness of a novel immunological agent used in solid organ transplantation. John has been a speaker and moderator at healthcare conferences featuring topics on healthcare technology commercialization, R&D innovation, and regulatory uncertainty.
As Chief Financial Officer, John oversees all financial planning and financing strategy for Putnam and runs the financial operations, accounting, control and reporting systems for the company. Prior to joining Putnam, he worked for an economics consulting firm providing expert testimony in matters of corporate and personal litigation. Currently John serves on the Board of Directors for the National Tay-Sachs & Allied Diseases Association, Inc. John earned a BA in economics summa cum laude, Phi Beta Kappa from Tufts University and an MBA from Harvard Business School.